About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Detection of Early Idiopathic Pulmonary Fibrosis

NCT03457935·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Temple University

With

Boehringer Ingelheim

Age

18–any

Sex

ALL

Healthy volunteers

Accepted

You may be eligible if

Informed consent
Subjects ≥ 40 y.o.
Naive patients with no IPF treatment
IPF diagnosis based on the ATS/ERS/JRS/ALAT criteria
Informed consent
Subjects ≥ 18 y.o.
ILD diagnosis

You may not be if

HIV
Hepatitis B
Hepatitis C
Pregnant or lactating women

The record

StatusActive not recruiting

PhaseNo phase

Taking part450

StartedApr 2018

UpdatedDec 29, 2025

Conditions

Idiopathic Pulmonary Fibrosis

Where1

Temple University
Philadelphia, Pennsylvania, United States

Clareo Health | Detection of Early Idiopathic Pulmonary Fibrosis